Evidence map›Paper›PMID 36930628›Full record

ArticlePloS one2023

Factors associated with prevalent Mycobacterium tuberculosis infection and disease among adolescents and adults exposed to rifampin-resistant tuberculosis in the household.

Soyeon Kim, Anneke C Hesseling, Xingye Wu, Michael D Hughes, N Sarita Shah, Sanjay Gaikwad, Nishi Kumarasamy, Erika Mitchell, Mey Leon, Pedro Gonzales and 17 more

Open access · goldFull text read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Preventing Multidrug-Resistant Tuberculosis: The Dawn of a New Era.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Review
  3. Article
  4. Prevalence of Tuberculosis Infection among Various Risk Groups in India: A Systematic Review and Meta-Analysis.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 19 institutions in 8 countries.

Soyeon KimDepartment of Biostatistics, Frontier Science Foundation, Brookline, Massachusetts, United States of America.ORCID 0000-0002-4776-6092
Anneke C HesselingFaculty of Medicine and Health Sciences, Department of Paediatrics and Child Health, Desmond Tutu TB Centre, Stellenbosch University, Cape Town, South Africa.
Xingye WuCenter for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Michael D HughesCenter for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
N Sarita ShahHubert Department of Global Health and Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, Georgia, United States of America.
Sanjay GaikwadByramjee Jeejeebhoy Government Medical College CRS and Sassoon General Hospital, BJMC Clinical Research Site, Pune, Maharashtra, India.
Nishi KumarasamyChennai Antiviral Research and Treatment (CART), Infectious Disease Medical Center, Voluntary Health Services, Chennai, India.
Erika MitchellDepartment of Medicine and University of Cape Town Lung Institute, Division of Pulmonology, University of Cape Town, Cape Town, South Africa.
Mey LeonBarranco CRS, Asociación Civil Impacta Salud y Educación, Lima, Peru.
Pedro GonzalesSan Miguel CRS, Asociación Civil Impacta Salud y Educación, Lima, Peru.
Sharlaa Badal-FaesenUniversity of the Witwatersrand CRS, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-7306-5732
Madeleine LourensTASK Applied Science CRS, Brooklyn Chest Hospital, Bellville, South Africa.
Sandy NeretteInstitute of Infectious Diseases and Reproductive Health, Les Centres GHESKIO, Port-au-Prince, Haiti.
Justin ShenjeSouth African Tuberculosis Vaccine Initiative, University of Cape Town, Cape Town, South Africa.ORCID 0000-0003-3054-3930
Petra de KokerFaculty of Medicine and Health Sciences, Department of Paediatrics and Child Health, Desmond Tutu TB Centre, Stellenbosch University, Cape Town, South Africa.
Supalert NedsuwanPHPT-Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand.
Lerato MohapiSoweto CRS, Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
Unoda A ChakalisaGaborone CRS, Princess Marina Hospital, Gaborone, Botswana.
Rosie MngqbisaDurban Adult HIV CRS, Enhancing Care Foundation, Durban University of Technology, Durban, South Africa.
Rodrigo Otávio da Silva EscadaInstituto Nacional de Infectologia Evandro Chagas, Fiocruz, Brazil.
Samuel OumaKenya Medical Research Institute, Kisumu, Kenya.
Barbara HeckmanFrontier Science Foundation, Amherst, New York, United States of America.
Linda NainiDepartment of Clinical Research and Bioscience, Social & Scientific Systems, Silver Spring, Maryland, United States of America.
Amita GuptaDepartment of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America.
Susan SwindellsDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
Gavin ChurchyardAurum Institute, Parktown, South Africa, School of Public Health, University of Witwatersrand, Johannesburg, South Africa, Vanderbilt University, Nashville, Tennessee, United States of America.
ACTG A5300/IMPAACT 2003 PHOENIx Feasibility Study Team
Asociación Civil Impacta Salud y Educación · PECancer Research And Biostatistics · USDesmond Tutu HIV Foundation · ZAFrontier Science & Technology Research Foundation · USUniversity of Cape Town · ZAUniversity of the Witwatersrand · ZAB. J. Medical College & Sassoon Hospital · INBrooklyn Chest Hospital · ZAChiangRai Prachanukroh Hospital · THDurban University of Technology · ZAEmory University · USGheskio Centers · HTInstituto Evandro Chagas · BRJohns Hopkins University · USKenya Medical Research Institute · KESocial and Scientific Systems (United States) · USUniversity of Nebraska Medical Center · USVanderbilt University · USVoluntary Health Services Hospital · IN

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Jennifer Jao, Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) GroupU01AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI JACKSON, J BROOKS · 2006 to 2010
$109.7M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$47.2M
Soweto Clinical Trials UnitUM1AI069453 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI Glenda E Gray, Lerato Mohapi · 2012 to 2026
$40.9M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGU01AI068616 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI SHAPIRO, DAVID ERIC · 2006 to 2010
$38.6M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
NIAID NIH HHS P30 AI168386NIAID NIH HHS U01 AI068616NIAID NIH HHS U01 AI068632NIAID NIH HHS U01 AI068634NIAID NIH HHS UM1 AI068616NIAID NIH HHS UM1 AI068632NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069453NIAID NIH HHS UM1 AI069456NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI069476NIAID NIH HHS UM1 AI106701NIAID NIH HHS UM1 AI106716NIAID NIH HHS UM1 AI154463NICHD NIH HHS HHSN275201800001CNICHD NIH HHS HHSN275201800001I
6 · The paper itself

Abstract

backgroundUnderstanding factors associated with prevalent Mycobacterium tuberculosis infection and prevalent TB disease in household contacts of patients with drug-resistant tuberculosis (TB) may be useful for TB program staff conducting contact investigations.

methodsUsing data from a cross-sectional study that enrolled index participants with rifampin-resistant pulmonary TB and their household contacts (HHCs), we evaluated HHCs age ≥15 years for factors associated with two outcomes: Mycobacterium tuberculosis infection and TB disease. Among HHCs who were not already diagnosed with current active TB disease by the TB program, Mycobacterium tuberculosis infection was determined by interferon-gamma release assay (IGRA). TB disease was adjudicated centrally. We fitted logistic regression models using generalized estimating equations.

resultsSeven hundred twelve HHCs age ≥15 years enrolled from 279 households in eight high-TB burden countries were a median age of 34 years, 63% female, 22% current smokers and 8% previous smokers, 8% HIV-positive, and 11% previously treated for TB. Of 686 with determinate IGRA results, 471 tested IGRA positive (prevalence 68.8% (95% Confidence Interval: 64.6%, 72.8%)). Multivariable modeling showed IGRA positivity was more common in HHCs aged 25-49 years; reporting prior TB treatment; reporting incarceration, substance use, and/or a period of daily alcohol use in the past 12 months; sharing a sleeping room or more evenings spent with the index participant; living with smokers; or living in a home of materials typical of low socioeconomic status. Forty-six (6.5% (95% Confidence Interval: 4.6%, 9.0%)) HHCs age ≥15 years had prevalent TB disease. Multivariable modeling showed higher prevalence of TB disease among HHCs aged ≥50 years; reporting current or previous smoking; reporting a period of daily alcohol use in the past 12 months; and reporting prior TB treatment.

conclusionWe identified overlapping and distinct characteristics associated with Mycobacterium tuberculosis infection and TB disease that may be useful for those conducting household TB investigations.

Indexed as

Mycobacterium tuberculosisTuberculosisTuberculosis, PulmonaryAdolescentAdultCross-Sectional StudiesDrug Resistance, BacterialFemaleHumansMaleRifampinRisk FactorsTuberculin TestRifampin

Identifiers

PMID36930628
PMCPMC10022776
OpenAlexW4327681632

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read284
identifiers read6
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.